Palvella Therapeutics (PVLA) has received a new Buy rating, initiated by TD Cowen analyst, Ritu Baral.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ritu Baral has given her Buy rating due to a combination of factors including the promising potential of Palvella Therapeutics’ QTORIN formulation platform. The platform is designed to produce treatments for rare genetic skin diseases, addressing significant unmet medical needs. One of the key assets in PVLA’s pipeline is the 3.9% QTORIN rapamycin, which is currently in Phase 3 trials for microcystic lymphatic malformation and Phase 2 trials for cutaneous venous malformation. The company is optimistic about the results expected in early 2026 and late 2025, respectively.
Furthermore, the QTORIN platform has been noted for its ability to optimize drug formulations by enhancing topical absorption while minimizing systemic exposure, addressing common challenges in topical drug delivery. This innovative approach could potentially lead to multiple commercially successful therapies. The projected peak sales of $956 million in the U.S. further support the Buy rating, indicating a strong market potential for PVLA’s offerings.
According to TipRanks, Baral is a 5-star analyst with an average return of 12.8% and a 48.50% success rate. Baral covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Insmed, and Alnylam Pharma.